Method for detecting a risk of hypertension and uses thereof
View Patent ↗This invention relates to a method for detecting a risk of hypertension and for targeting antihypertensive treatment in a subject, the method comprising isolating genomic DNA from said subject, determining the DNA sequence comprising a nucleotide sequence encoding a variant α 2B -adrenoceptor protein.
1. A method for detecting a risk of hypertension in a subject having a family a history of hypertension by determining the pattern of alleles encoding a variant α 2B -adrenoceptor, comprising the steps of:
a) providing a biological sample of the subject to be tested; and
b) performing an assay on the biological sample for dectecting in the biological sample the presence of
i) the insertion/insertion (I/I) or deletion/insertion (D/I) genotypes of the human α 2B -adrenoceptor, or
ii) the D/D genotype of the human α 2B -adrenoceptor, wherein the presence of the D/D genotype indicates an increased risk of hypertension in said subject.
2. The method according to claim 1 , wherein the assay is a DNA-assay.
3. The method according to claim 1 or 2 , wherein the assay is carried out using a gene or DNA chip, microarray, strip, panel or similar combination of more than one genes, mutations or RNA expressions to be assayed.
4. The method according to claim 1 , wherein the allelic pattern is determined using polymerase chain reaction.
5. The method according to claim 1 , wherein the biological sample is a blood sample or buccal sweep sample and genomic DNA is isolated from the said sample.
6. The method according to claim 1 , wherein the assay is based on a capturing probe which comprises a single strand of the cDNA, comprising a nucleotide sequence encoding a variant α 2B -adrenoceptor protein with a deletion of at least 1 glutamate from a glutamic acid repeat element of 12 glutamates, amino acids 298–309, in an acidic stretch of 18 amino acids 294–311, located in the 3 rd intracellular loop of the receptor polypeptide.
7. The method according to claim 1 , wherein the assay is based on a capturing probe which comprises a single strand of the cDNA corresponding to the α 2B -adrenoceptor without the deletion of a glutamate from a glutamic acid repeat element of 12 glutamates, amino acids 298–309, in an acidic stretch of 18 amino acids 294–311, located in the 3 rd intracellular loop of the receptor polypeptide.
8. The method according to claim 1 , wherein the method is used for determining whether a subject will benefit from treatment with a drug affecting the noradrenaline sensitivity or sympathetic activity of the subject.
9. The method according to claim 1 , wherein the method is used for determining whether a subject will benefit from treatment with an α 2B -adrenoceptor antagonist.
10. The method according to claim 1 , wherein the method is used for determining whether a subject will be at increased risk of adverse effects if subtype-nonselective α 2 -agonists or a diuretic or a calcium channel blocker are administered to them.
11. The method according to claim 1 , further comprising the step of selecting a subject of the D/D genotype for clinical drug trials testing the antihypertensive effects of compounds.
12. The method according to claim 11 , wherein the compound is a drug affecting the noradrenaline sensitivity or sympathetic activity of the subject.
13. The method according to claim 8 or 11 , wherein the compound is a drug modulating, inhibiting or activating the vascular alpha- or beta-adrenergic receptors of the subjects either directly or through central nervous system effects.
14. The method according to claim 8 or 11 , wherein the compound is an angiotensin converting enzyme (ACE) inhibitor, angiotensin II inhibitor or angiotensin receptor inhibitor.
15. The method according to claim 13 , wherein the compound is an α 2B -selective or α 2B -nonselective α 2 -adrenoceptor antagonist.
16. A method for targeting the treatment of hypertension in a hypertensive subject having a family history of hypertension by determining the pattern of alleles encoding a said variant α 2B -adrenoceptor in accordance with the method of, claim 1 , and treating a subject having the D/D genotype with a drug affecting the noradrenaline sensitivity or sympathetic activity of the subject.
17. The method according to claim 16 , wherein the said drug is a drug modulating, inhibiting or activating the vascular alpha- or beta-adrenergic receptors of the subjects either directly or through central nervous system effects.
18. The method according to claim 17 , wherein the said drug is pindolol, propranolol, sotalol, timolol, acebutolol, atenol, betaxolol, bisoprol, esmolol, metoprolol, seliprol, carvedilol, labetalol, clonidine, moxonidine, prazosin, or indapamid.
19. The method according to claim 16 , wherein the said drug is an angiotensin converting enzyme (ACE) inhibitor, angiotensin II inhibitors or angiotensin receptor inhibitor.
20. The method according to claim 19 , wherein the said drug is captopril, cinapril, enalapril, imidapril, lisinopril, moexipril, perindopril, ramipril, trandolapril, candesartan, eprosartan, irbesartan, losartan, valsartan or telmisartan.
21. A method according to claim 17 , wherein the said drug is an α 2B -selective or α 2B -nonselective α 2 -adrenoceptor or α-adrenoceptor antagonist.